Administration with an FDFT1 inhibitor TAK-475 (1-[2-[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic acid, lapaquistat acetate) reduces subcutaneous transplanted pancreatic tumor cell growth and incubation of 3D pancreatic tumor cells with TAK-475 reduces activation of the Akt signaling pathway [43]. This evidence concerns the gene AKT1 and pancreatic neoplasm.